Sign in
4

Changes in Ownership

NEKTAR THERAPEUTICS Filed Acc 0001209191-22-057968

Chief R&D Officer sold 13,460 shares at $3.57 ($48,052)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Zalevsky Jonathan Chief R&D Officer 2022-11-16 Sale −13,460 $3.57 $48,052 313,663 D
Open-market sales · 13,460 sh · avg $3.57 · $48,052
Loading xslF345X03/doc4.xml…